Tenon Medical Inc

Tenon Medical Inc(TNON)股票分析

$1.770

+0.117 (+6.63%)收盤時

Loading chart…
最高
1.800
開盤
1.660
成交量加權均價
1.74
成交量
94.11K
市值
2.31M
最低
1.650
成交金額
163.75K
企業價值/稅息折舊攤銷前利潤(TTM)
-0.37

Tenon Medical, Inc. is a medical device company. The Company has developed the Catamaran SI Joint Fusion System that offers a novel, less invasive approach to the SI joint using a single, robust titanium implant. The system features the Catamaran Fixation Device which passes through both the axial and sagittal planes of the ilium and sacrum, stabilizing and transfixing the SI Joint along its longitudinal axis. The angle and trajectory of the Catamaran surgical approach is also designed to provide a pathway away from critical neural and vascular structures and into the strongest cortical bone. Its trademarks include Catamaran, PiSIF, CAT PiSIF, ETAD, CAT SIJ Fusion System, SImmetry, MAINSAIL, SImmetry+, Catamaran Transfixation Fusion Device, Catamaran Transfixation Fusion System, and others. The Catamaran SI Joint Fusion System offers a novel, less invasive Inferior-Posterior approach to the SI joint using a single, robust titanium implant.

AI 分析 of Tenon Medical Inc (TNON)

賣出

Tenon Medical Inc is not a good buy right now due to its extremely low RSI of 13.34, indicating it is oversold, and a staggering year-to-date change of -95.13%. The stock is trading at $1.66, significantly below its 52-week high of $45.50, which reflects a severe decline in value. The company has also reported consistent net losses, with the latest EPS at -12.35, and a forward P/E ratio of 0, suggesting no earnings growth is expected in the near term. The main risk is the negative sentiment surrounding its financing activities, which caused a 4.79% drop in pre-market trading after the announcement of a securities purchase agreement.

估值指標

Tenon Medical Inc(TNON)目前預期本益比為 0.00,5 年平均預期本益比為 -3.02。

預期本益比

合理
5 年均值 P/E
-3.02
目前P/E
0.00
高估
12.73
低估
-18.77

預期 EV/EBITDA

嚴重低估
5 年均值 EV/EBITDA
-0.05
目前EV/EBITDA
-0.37
高估
0.06
低估
-0.17

預期股價營收比

合理
5 年均值 P/S
5.63
目前P/S
0.50
高估
36.11
低估
-24.85

Alphio AI 對 TNON 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%TNON

$1.25

情境價格

基

基準

基準 · 50%TNON

$1.02

情境價格

悲

悲觀

悲觀 · 25%TNON

$0.83

情境價格

事件時間軸

2026-10-28 (ET)

09:25:00

Tenon Medical Completes Initial Alpha Cases for Quickstep

2026-10-15 (ET)

09:00:00

Tenon Medical Secures 8 New Patents

2026-10-05 (ET)

06:30:00

Selling Stockholders Plan to Sell 858,269 Shares of Common Stock

2026-09-30 (ET)

09:00:00

Tenon Medical Launches New Titanium 3D-Printed Lateral Screw

2026-09-11 (ET)

11:00:00

Tenon Medical Inc Trading Halted

資訊

TNON 常見問題 —— 由 Alphio AI 解答

Tenon Medical, Inc. is a medical device company. The Company has developed the Catamaran SI Joint Fusion System that offers a novel, less invasive approach to the SI joint using a single, robust titanium implant. The system features the Catamaran Fixation Device which passes through both the axial and sagittal planes of the ilium and sacrum, stabilizing and transfixing the SI Joint along its longitudinal axis. The angle and trajectory of the Catamaran surgical approach is also designed to provide a pathway away from critical neural and vascular structures and into the strongest cortical bone. Its trademarks include Catamaran, PiSIF, CAT PiSIF, ETAD, CAT SIJ Fusion System, SImmetry, MAINSAIL, SImmetry+, Catamaran Transfixation Fusion Device, Catamaran Transfixation Fusion System, and others. The Catamaran SI Joint Fusion System offers a novel, less invasive Inferior-Posterior approach to the SI joint using a single, robust titanium implant. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Tenon Medical Inc is not a good buy right now due to its extremely low RSI of 13.34, indicating it is oversold, and a staggering year-to-date change of -95.13%. The stock is trading at $1.66, significantly below its 52-week high of $45.50, which reflects a severe decline in value. The company has also reported consistent net losses, with the latest EPS at -12.35, and a forward P/E ratio of 0, suggesting no earnings growth is expected in the near term. The main risk is the negative sentiment surrounding its financing activities, which caused a 4.79% drop in pre-market trading after the announcement of a securities purchase agreement.

註冊或登入後參與討論

相關文章

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易